Trials / Completed
CompletedNCT03111420
Study of AggreGuide A-100 (ADP) Assay
Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Detection of Platelet Dysfunction Due to P2Y12 Antiplatelet Drugs
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 280 (actual)
- Sponsor
- Aggredyne, Inc. · Industry
- Sex
- All
- Age
- 22 Years – 74 Years
- Healthy volunteers
- Accepted
Summary
Study to evaluate the performance of the AggreGuide A-100 ADP assay for detection of platelet dysfunction caused by P2Y12 inhibitor antiplatelet therapy.
Detailed description
Study subjects will have A-100 ADP measurements performed at baseline and after initiation of P2Y12 inhibitor antiplatelet therapy, following loading and maintenance doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | P2Y12 inhibitor | Administration of P2Y12 inhibitor antiplatelet therapy |
| DEVICE | Platelet function test | Blood is drawn for testing of platelet aggregation activity |
Timeline
- Start date
- 2017-01-09
- Primary completion
- 2018-06-01
- Completion
- 2018-06-01
- First posted
- 2017-04-12
- Last updated
- 2019-02-21
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03111420. Inclusion in this directory is not an endorsement.